{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:23:12Z","timestamp":1792153392775,"version":"4.4.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,27]]},"DOI":"10.1097\/tp.0b013e3181b11b72","type":"journal-article","created":{"date-parts":[[2009,8,15]],"date-time":"2009-08-15T03:16:59Z","timestamp":1250306219000},"page":"568-574","source":"Crossref","is-referenced-by-count":172,"title":["HLA-Specific Antibodies Developed in the First Year Posttransplant are Predictive of Chronic Rejection and Renal Graft Loss"],"prefix":"10.1097","volume":"88","author":[{"given":"Po-Chang","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul I.","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Everly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210211","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies.","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation"},{"key":"R2-18-20210211","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/01.TP.0000055833.65192.3B","article-title":"Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome.","volume":"75","author":"Worthington","year":"2003","journal-title":"Transplantation"},{"key":"R3-18-20210211","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1111\/j.1600-6143.2005.01016.x","article-title":"Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure.","volume":"5","author":"Mizutani","year":"2005","journal-title":"Am J Transplant"},{"key":"R4-18-20210211","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1600-6143.2006.01721.x","article-title":"The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients.","volume":"7","author":"Mizutani","year":"2007","journal-title":"Am J Transplant"},{"key":"R5-18-20210211","first-page":"255","article-title":"Detection of HLA and MICA antibodies before kidney graft failure.","author":"Mizutani","year":"2006","journal-title":"Clin Transpl"},{"key":"R6-18-20210211","first-page":"265","article-title":"Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience.","author":"Ozawa","year":"2006","journal-title":"Clin Transpl"},{"key":"R7-18-20210211","first-page":"291","article-title":"Retrospective antibody analysis of thirty patients with kidney graft failure.","author":"Kinukawa","year":"2006","journal-title":"Clin Transpl"},{"key":"R8-18-20210211","first-page":"305","article-title":"Longitudinal testing of seventy-six renal allograft patients for HLA antibodies: Maastricht experience.","author":"van den Berg-Loonen","year":"2006","journal-title":"Clin Transpl"},{"key":"R9-18-20210211","first-page":"455","article-title":"Summary of the effect of de novo HLA antibodies on chronic kidney graft failure.","author":"Terasaki","year":"2006","journal-title":"Clin Transpl"},{"issue":"69 suppl 1","key":"R10-18-20210211","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1399-0039.2006.00765.x","article-title":"14th International HLA and immunogenetics workshop: Report on the prospective chronic rejection project.","author":"Ozawa","year":"2007","journal-title":"Tissue Antigens"},{"key":"R11-18-20210211","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/204998b0","article-title":"Microdroplet assay of human serum cytotoxins.","volume":"204","author":"Terasaki","year":"1964","journal-title":"Nature"},{"key":"R12-18-20210211","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM196904032801401","article-title":"Significance of the positive crossmatch test in kidney transplantation.","volume":"280","author":"Patel","year":"1969","journal-title":"N Engl J Med"},{"key":"R13-18-20210211","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1046\/j.1600-6135.2003.00273.x","article-title":"Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs risk.","volume":"3","author":"Gebel","year":"2003","journal-title":"Am J Transplant"},{"key":"R14-18-20210211","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival.","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am J Transplant"},{"key":"R15-18-20210211","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/j.1600-6143.2008.02303.x","article-title":"Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys.","volume":"8","author":"Smith","year":"2008","journal-title":"Am J Transplant"},{"key":"R16-18-20210211","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(00)03569-8","article-title":"Endothelial cell chimerism after renal transplantation and vascular rejection.","volume":"357","author":"Lagaaij","year":"2001","journal-title":"Lancet"},{"key":"R17-18-20210211","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.humimm.2007.04.003","article-title":"Accommodation of grafts: Implications for health and disease.","volume":"68","author":"Tang","year":"2007","journal-title":"Hum Immunol"},{"key":"R18-18-20210211","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-3089.2006.00278.x","article-title":"Present status of ABO-incompatible kidney transplantation in Japan.","volume":"13","author":"Takahashi","year":"2006","journal-title":"Xenotransplantation"},{"key":"R19-18-20210211","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1111\/j.1600-6143.2008.02428.x","article-title":"Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes.","volume":"8","author":"Bartel","year":"2008","journal-title":"Am J Transplant"},{"key":"R20-18-20210211","first-page":"219","article-title":"HLA antibodies and soluble CD30 are associated with poor renal graft outcome: Updated results of a single-center cross-sectional study.","author":"Langan","year":"2006","journal-title":"Clin Transpl"},{"key":"R21-18-20210211","first-page":"171","article-title":"Donor-specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four-year follow-up.","author":"Lachmann","year":"2006","journal-title":"Clin Transpl"},{"key":"R22-18-20210211","first-page":"201","article-title":"Anti-HLA class II antibodies and chronic allograft nephropathy.","author":"Gerbase-DeLima","year":"2006","journal-title":"Clin Transpl"},{"key":"R23-18-20210211","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1034\/j.1600-6143.2002.020204.x","article-title":"Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation.","volume":"2","author":"Pelletier","year":"2002","journal-title":"Am J Transplant"},{"key":"R24-18-20210211","first-page":"349","article-title":"The role of HLA-specific antibodies in kidney transplant rejection: Published studies and local data.","author":"Worthington","year":"2006","journal-title":"Clin Transpl"},{"key":"R25-18-20210211","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/TP.0b013e3181837626","article-title":"Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels.","volume":"86","author":"Issa","year":"2008","journal-title":"Transplantation"},{"key":"R26-18-20210211","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1111\/j.1600-6143.2006.01503.x","article-title":"Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure.","volume":"6","author":"Campos","year":"2006","journal-title":"Am J Transplant"},{"key":"R27-18-20210211","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1600-6143.2006.01691.x","article-title":"Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival.","volume":"7","author":"Langan","year":"2007","journal-title":"Am J Transplant"},{"key":"R28-18-20210211","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1523-1755.2001.059002488.x","article-title":"Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium.","volume":"59","author":"Muczynski","year":"2001","journal-title":"Kidney Int"},{"key":"R29-18-20210211","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00007890-199203000-00011","article-title":"The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody.","volume":"53","author":"Halloran","year":"1992","journal-title":"Transplantation"},{"key":"R30-18-20210211","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/01.ASN.0000061778.08085.9F","article-title":"Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: Characterization, isolation, and regulation of MHC class II expression.","volume":"14","author":"Muczynski","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R31-18-20210211","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/TP.0b013e318186d87b","article-title":"\u201cNatural\u201d human leukocyte antigen antibodies found in nonalloimmunized healthy males.","volume":"86","author":"Morales-Buenrostro","year":"2008","journal-title":"Transplantation"},{"key":"R32-18-20210211","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"R33-18-20210211","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-6143.2008.02461.x","article-title":"Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.","volume":"9","author":"Perry","year":"2008","journal-title":"Am J Transplant"},{"key":"R34-18-20210211","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/TP.0b013e3181a4b91b","article-title":"Abrogation of anti-HLA antibodies via proteasome inhibition.","volume":"87","author":"Trived","year":"2009","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200908270-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:48Z","timestamp":1786039428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200908270-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,27]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181b11b72","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8,27]]}}}